Skip to content
← All treatment topics

TREATMENT READING

Childhood Basal Cell Carcinoma and Squamous Cell Carcinoma of the Skin

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

Health professional

Special Considerations for the Treatment of Children With Cancer

Source: Childhood Basal Cell Carcinoma and Squamous Cell Carcinoma of the Skin Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: September 11, 2024. Captured 2026-09-09.

Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:

Sources: 1

Primary care physicians.

Pediatric surgeons.

Pathologists.

Pediatric radiation oncologists.

Pediatric medical oncologists and hematologists.

Ophthalmologists.

Rehabilitation specialists.

Pediatric oncology nurses.

Social workers.

Child-life professionals.

Psychologists.

Nutritionists.

For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.

Sources: Supportive and Palliative Care

The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.

Sources: 2 · NCI website

Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.[3-5] Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment. For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.

Sources: 3 · 5 · Late Effects of Treatment for Childhood Cancer

Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.[6] The U.S. Rare Diseases Act of 2002 defines a rare disease as one that affects populations smaller than 200,000 people in the United States. Therefore, all pediatric cancers are considered rare.

Sources: 6 · Rare Diseases Act of 2002

The designation of a rare tumor is not uniform among pediatric and adult groups. In adults, rare cancers are defined as those with an annual incidence of fewer than six cases per 100,000 people. They account for up to 24% of all cancers diagnosed in the European Union and about 20% of all cancers diagnosed in the United States.[7,8] In children and adolescents, the designation of a rare tumor is not uniform among international groups, as follows:

Sources: 7 · 8

A consensus effort between the European Union Joint Action on Rare Cancers and the European Cooperative Study Group for Rare Pediatric Cancers estimated that 11% of all cancers in patients younger than 20 years could be categorized as very rare. This consensus group defined very rare cancers as those with annual incidences of fewer than two cases per 1 million people. However, three additional histologies (thyroid carcinoma, melanoma, and testicular cancer) with incidences of more than two cases per 1 million people were also included in the very rare group due to a lack of knowledge and expertise in the management of these tumors.[9]

Sources: 9

The Children's Oncology Group defines rare pediatric cancers as those listed in the International Classification of Childhood Cancer subgroup XI, which includes thyroid cancers, melanomas and nonmelanoma skin cancers, and multiple types of carcinomas (e.g., adrenocortical carcinomas, nasopharyngeal carcinomas, and most adult-type carcinomas such as breast cancers and colorectal cancers).[10] These diagnoses account for about 5% of the cancers diagnosed in children aged 0 to 14 years and about 27% of the cancers diagnosed in adolescents aged 15 to 19 years.[4] Most cancers in subgroup XI are either melanomas or thyroid cancers, with other cancer types accounting for only 2% of the cancers diagnosed in children aged 0 to 14 years and 9.3% of the cancers diagnosed in adolescents aged 15 to 19 years.

Sources: 10 · 4

These rare cancers are extremely challenging to study because of the relatively few patients with any individual diagnosis, the predominance of rare cancers in the adolescent population, and the small number of clinical trials for adolescents with rare cancers.

Information about these tumors may also be found in sources relevant to adults with cancer, such as Skin Cancer Treatment.

Sources: Skin Cancer Treatment

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional

Treatment of Childhood Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) of the Skin

Source: Childhood Basal Cell Carcinoma and Squamous Cell Carcinoma of the Skin Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: September 11, 2024. Captured 2026-09-09.

Treatment options for childhood BCC and SCC of the skin include the following:

Surgery.

Sources: Surgery

Targeted therapy.

Sources: Targeted therapy

Health professional · Treatment of Childhood Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) of the Skin

Surgery

Source: Childhood Basal Cell Carcinoma and Squamous Cell Carcinoma of the Skin Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: September 11, 2024. Captured 2026-09-09.

Treatment for nonmelanoma skin cancer is predominantly surgical, either surgical excision or Mohs micrographic surgery.[1]

Sources: 1

Health professional · Treatment of Childhood Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) of the Skin

Targeted Therapy

Source: Childhood Basal Cell Carcinoma and Squamous Cell Carcinoma of the Skin Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: September 11, 2024. Captured 2026-09-09.

Most BCCs have activation of the hedgehog pathway, generally resulting from variants in PTCH1. For more information about PTCH1, see Genetics of Skin Cancer.[2]

Sources: Genetics of Skin Cancer · 2

Vismodegib. In adults, vismodegib (GDC-0449), a hedgehog pathway inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic or advanced BCC.[3-5] This drug also reduces the tumor burden in patients with basal cell nevus syndrome.[6] In a case report, one child with xeroderma pigmentosum and a nodular BCC achieved a complete clinical response with vismodegib.[7]

Sources: 3 · 5 · 6 · 7

Cemiplimab. No prospective trials of cemiplimab (PD-1 inhibitor) have been conducted in children and adolescents. However, the FDA approved cemiplimab for use in patients with metastatic or locally advanced cutaneous SCC who are not candidates for surgery or radiation and in patients with locally advanced or metastatic BCC previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate.[8,9]

Sources: 8 · 9

For more information, see Skin Cancer Treatment.

Sources: Skin Cancer Treatment

Health professional

Treatment Options Under Clinical Evaluation for Childhood Basal Cell Carcinoma and Squamous Cell Carcinoma of the Skin

Source: Childhood Basal Cell Carcinoma and Squamous Cell Carcinoma of the Skin Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: September 11, 2024. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

For patients

Treatment of Childhood Basal Cell Carcinoma and Squamous Cell Carcinoma of the Skin

Source: Childhood Basal Cell Carcinoma and Squamous Cell Carcinoma of the Skin Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: November 2, 2020. Captured 2026-09-09.

The main treatment for basal cell carcinoma and squamous cell carcinoma of the skin is surgery. Two types of surgery may be used:

Sources: basal cell carcinoma · squamous cell carcinoma of the skin · surgery

Excision: The tumor and a small amount of healthy tissue around the tumor is removed.

Sources: Excision · tumor · tissue

Mohs micrographic surgery: The tumor is cut from the skin in thin layers. During surgery, the edges of the tumor and each layer of tumor removed are viewed through a microscope to check for cancer cells. Layers continue to be removed until no more cancer cells are seen. This type of surgery removes as little normal tissue as possible and is often used to remove skin cancer on the face.

Sources: Mohs micrographic surgery · microscope · cancer · cells · skin cancer

Studies

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

NCT03430843 · COMPLETED · phase3

Esophageal Squamous Cell Carcinoma (ESCC)

ClinicalTrials.gov record

A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)

NCT03597295 · COMPLETED · phase2

Squamous Cell Carcinoma of Anal Canal

ClinicalTrials.gov record

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

NCT03783442 · COMPLETED · phase3

Esophageal Squamous Cell Carcinoma (ESCC)

ClinicalTrials.gov record

Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer

NCT00274937 · COMPLETED · phase3

Stage I Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7, Stage I Nasopharyngeal Undifferentiated Carcinoma AJCC v7, Stage II Nasopharyngeal Keratinizing Squamous...

ClinicalTrials.gov record

Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar

NCT00476476 · COMPLETED · phase2

Squamous Cell Carcinoma

ClinicalTrials.gov record

A Pilot Study of Acupuncture Treatment for Dysphagia

NCT00797732 · COMPLETED · na

Carcinomas, Squamous Cell, Dysphagia

ClinicalTrials.gov record

Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma

NCT02837042 · TERMINATED · phase2

Penile Squamous Cell Carcinoma

ClinicalTrials.gov record

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

NCT03108131 · COMPLETED · phase2

Skin Squamous Cell Carcinoma, Appendix Adenocarcinoma, Rare Lesion, Locally Advanced Malignant Neoplasm, Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Malignant...

ClinicalTrials.gov record

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

NCT03260023 · ACTIVE NOT RECRUITING · phase1, phase2

HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell...

ClinicalTrials.gov record

IRX-2 Regimen in Treating Women With Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3

NCT03267680 · TERMINATED · phase2

Cervical Squamous Cell Carcinoma In Situ, Vulvar High Grade Squamous Intraepithelial Lesion

ClinicalTrials.gov record

Margin-Based Vs. Robust Photon Radiotherapy Planning in IMRT of HN-SQCC

NCT03552965 · COMPLETED · na

Squamous Cell Carcinoma of the Head and Neck

ClinicalTrials.gov record

Disease and treatment settings

ERBITUX: metastatic squamous cell carcinoma

Disease and treatment setting

( 1.1 , 14.1 ) Recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil.

ERBITUX: metastatic squamous cell carcinoma (first-line)

Disease and treatment setting

1.1 Squamous Cell Carcinoma of the Head and Neck (SCCHN) ERBITUX ® is indicated: in combination with radiation therapy for the initial treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN). in...

OPDIVO QVANTIG: metastatic squamous cell carcinoma after prior therapy

Disease and treatment setting

1.7 Squamous Cell Carcinoma of the Head and Neck OPDIVO QVANTIG, as monotherapy, is indicated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression...

OPDIVO QVANTIG: unresectable metastatic squamous cell carcinoma with PD-L1 stated without a specific alteration (first-line)

Disease and treatment setting

OPDIVO QVANTIG, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC)...

OPDIVO: metastatic squamous cell carcinoma after prior therapy

Disease and treatment setting

1.9 Squamous Cell Carcinoma of the Head and Neck OPDIVO is indicated for the treatment of adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) with disease progression on or after...

OPDIVO: unresectable metastatic squamous cell carcinoma after prior therapy

Disease and treatment setting

• OPDIVO is indicated for the treatment of adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy.

OPDIVO: unresectable metastatic squamous cell carcinoma with PD-L1 stated without a specific alteration (first-line)

Disease and treatment setting

• OPDIVO, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose...

Recurrent Paranasal Sinus Squamous Cell Carcinoma

Disease and treatment setting

Recurrent Paranasal Sinus Squamous Cell Carcinoma

Squamous Cell Carcinoma

Disease and treatment setting

Squamous Cell Carcinoma

Stage IVC Sinonasal Squamous Cell Carcinoma AJCC v7

Disease and treatment setting

Stage IVC Sinonasal Squamous Cell Carcinoma AJCC v7

TEVIMBRA: unresectable metastatic squamous cell carcinoma after prior therapy

Disease and treatment setting

as a single agent in adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor.

ZYNYZ: metastatic squamous cell carcinoma (first-line)

Disease and treatment setting

1.1 Squamous Cell Carcinoma of the Anal Canal ZYNYZ, in combination with carboplatin and paclitaxel, is indicated for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of...

Drug labels

Condylox

Label date 2024-01-29

INDICATIONS AND USAGE Condylox Gel 0.5% is indicated for the topical treatment of anogenital warts (external genital warts and perianal warts). This product is not indicated in the treatment of mucous membrane warts (see PRECAUTIONS )....

DailyMed label